Cartesian Therapeutics, Inc.

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Current securities

1. Regulation FD Disclosure · Other EventsSep 29, 2026
2. Results of Operations and Financial ConditionAug 6, 2026
3. Submission of Matters to a Vote of Security HoldersJun 17, 2026
4. 144 filingJun 9, 2026
5. Regulation FD DisclosureJun 9, 2026